Sentry Investment Management LLC Invests $59,000 in Teleflex Incorporated (NYSE:TFX)

Sentry Investment Management LLC acquired a new position in Teleflex Incorporated (NYSE:TFX) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 237 shares of the medical technology company’s stock, valued at approximately $59,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Teleflex in the first quarter worth about $2,467,000. ProShare Advisors LLC increased its position in shares of Teleflex by 34.1% in the 1st quarter. ProShare Advisors LLC now owns 12,200 shares of the medical technology company’s stock valued at $2,759,000 after acquiring an additional 3,105 shares during the period. Tidal Investments LLC raised its stake in Teleflex by 214.7% in the 1st quarter. Tidal Investments LLC now owns 6,644 shares of the medical technology company’s stock worth $1,503,000 after acquiring an additional 4,533 shares during the last quarter. Boston Trust Walden Corp lifted its position in Teleflex by 2.7% during the 2nd quarter. Boston Trust Walden Corp now owns 233,913 shares of the medical technology company’s stock worth $49,199,000 after acquiring an additional 6,076 shares during the period. Finally, Russell Investments Group Ltd. grew its stake in Teleflex by 15.8% during the 1st quarter. Russell Investments Group Ltd. now owns 18,838 shares of the medical technology company’s stock valued at $4,245,000 after purchasing an additional 2,570 shares during the last quarter. 95.62% of the stock is currently owned by hedge funds and other institutional investors.

Teleflex Stock Performance

TFX opened at $203.50 on Wednesday. The stock has a market cap of $9.45 billion, a P/E ratio of 40.46, a P/E/G ratio of 2.12 and a beta of 1.18. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.42 and a quick ratio of 1.39. The firm has a fifty day moving average price of $238.09 and a 200 day moving average price of $224.11. Teleflex Incorporated has a 1 year low of $195.51 and a 1 year high of $257.85.

Teleflex (NYSE:TFX) last issued its quarterly earnings data on Thursday, October 31st. The medical technology company reported $3.49 earnings per share for the quarter, topping analysts’ consensus estimates of $3.38 by $0.11. The business had revenue of $764.40 million during the quarter, compared to the consensus estimate of $768.68 million. Teleflex had a net margin of 7.85% and a return on equity of 14.19%. The company’s revenue was up 2.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.64 earnings per share. Equities research analysts anticipate that Teleflex Incorporated will post 13.98 earnings per share for the current year.

Teleflex Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 16th. Shareholders of record on Friday, November 15th will be given a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a yield of 0.67%. The ex-dividend date of this dividend is Friday, November 15th. Teleflex’s dividend payout ratio is presently 27.04%.

Insider Buying and Selling at Teleflex

In other news, Director Stuart A. Randle sold 2,674 shares of the business’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $238.93, for a total transaction of $638,898.82. Following the completion of the sale, the director now owns 5,496 shares of the company’s stock, valued at $1,313,159.28. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 1.43% of the company’s stock.

Analyst Ratings Changes

TFX has been the subject of several research analyst reports. Royal Bank of Canada reduced their price objective on Teleflex from $275.00 to $245.00 and set an “outperform” rating for the company in a research note on Friday, November 1st. Truist Financial restated a “hold” rating and set a $227.00 price objective (down from $255.00) on shares of Teleflex in a research note on Monday. Stephens upped their price objective on shares of Teleflex from $275.00 to $290.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Needham & Company LLC reissued a “hold” rating on shares of Teleflex in a report on Friday, November 1st. Finally, Mizuho lowered their price target on shares of Teleflex from $275.00 to $250.00 and set a “neutral” rating on the stock in a report on Friday, November 1st. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $259.25.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.